SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Innate Pharma Shifts PACIFIC-9 Trial Readout to H1 2027

AstraZeneca now expects high-level data from the Phase 3 PACIFIC-9 trial in H1 2027, revised from H2 2026. Enrollment is complete, and the study is event-driven.

IPH

Related stories